BLAINJECTIONINJECTABLE
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLTEZO (adalimumab-adbm) is a monoclonal antibody TNF inhibitor approved in 2017 as a biosimilar to Humira. It is used to treat rheumatoid arthritis, psoriasis, Crohn's disease, and other inflammatory conditions by blocking tumor necrosis factor-alpha. The drug is administered via subcutaneous injection.
Peak
Product is at peak lifecycle stage; commercial teams are focused on market penetration and maintaining formulary status against competing biosimilars.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYLTEZO involves executing a competitive biosimilar strategy in a crowded marketplace where differentiation depends on payer relationships, formulary position, and commercial execution rather than clinical innovation. Career progression will be driven by market share capture and defensive positioning against competitors.
Brand ManagerMedical Science Liaison
Worked on CYLTEZO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.